StockIQpro
NASDAQ:ALGS

Aligos Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Aligos Therapeutics, Inc.'s revenue fell 39.5% in fiscal 2025 to $2.2M while operating margin fell to −4024.9%, its lowest in 3 years. The diluted share count rose 57.8%.Summary generated from Aligos Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 5, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$2.2M
Revenue growth−39.5%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−4024.9%
Net margin−1106.7%
ROICn/a
Return on equity−196.9%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+57.8%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue00642
Operating income−128−98−88−89−88
Net income−128−96−88−131−24
Free cash flow−117−80−79−81n/a

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)